# US 2024/0173414 A1 · Photodynamic therapy comprising two light exposures at different wavelengths

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173414 A1
- Document ID: US20240173414A1
- Status: Published application
- Kind: A1
- Application number: 18/188,373
- Filed: 2023-03-22
- Published: 2024-05-30
- Earliest claimed: 2021-02-19
- Assignees: Biofrontera Bioscience GmbH
- Applicants: Biofrontera Bioscience GmbH
- Inventors: Hermann LÜBBERT
- Web page: https://patentgrep.com/patent/US20240173414A1

## CPC

- A61K 41/0061: {5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61N 5/0616: {Skin treatment other than tanning}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C07C 229/22: the carbon skeleton being further substituted by oxygen atoms
- C07D 487/22: in which the condensed system contains four or more hetero rings
- A61N 2005/0663: {Coloured light}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of preventing or treating a dermatological disease in a patient, the method comprises the following order of steps:
(a) topical application or subcutaneous injection of a composition comprising a photosensitizer to an area of the skin of said patient,
(b) exposure of at least said area of the skin to light having a wavelength spectrum of 360 nm to 460 nm for a duration of 30 min to 5 hours, and
(c) exposure of at least said area of the skin to light having a wavelength spectrum of 570 nm to 670 nm.

### Claim 22 (depends on 21)

The method of claim 21, wherein the composition is formulated as a nanoemulsion comprising:
(a) at least one aqueous component, and
(b) a carrier, which comprises:
(i) at least one lipophilic component,
(ii) at least one surfactant and
(iii) at least one alcohol.

### Claim 23 (depends on 22)

The method of claim 22, wherein
the carrier is present in the aqueous component and/or
the surfactant is present in an amount of from 1% by weight to 30% by weight and the alcohol is present in an amount of from 0.1% by weight to 10% by weight, based on the total weight of the nanoemulsion.

### Claim 24 (depends on 22)

The method of claim 22, wherein the aqueous component is present in an amount of from 50% by weight to 98% by weight, based on the total weight of the nanoemulsion.

### Claim 25 (depends on 22)

The method of claim 22, wherein:
the at least one alcohol is isopropylalcohol and/or 1-propylalcohol and/or
the at least one lipophilic component are triglycerides and/or a mixture thereof and/or
the at least one surfactant is lecithin and/or a polyoxyethylene-type surfactant and/or
the mean diameter of particles of the nanoemulsion ranges from 10 to 100 nm.

### Claim 26 (depends on 22)

The method of claim 22, wherein the photosensitizer is selected from 5-aminolevulinic acid (ALA), ALA-esters, in particular methyl-5-amino-4-oxopentanoat, or hexyl-5-amino-4-oxopentanoat or their derivatives.

### Claim 27 (depends on 21)

The method of claim 21, wherein the light used in step (c) has a wavelength spectrum of 570 nm to about 635 nm.

### Claim 28 (depends on 21)

The method of claim 21, wherein the area of the skin comprises skin affected by the disease or skin prone to be affected by the disease.

### Claim 29 (depends on 21)

The method of claim 21, wherein there is a residence time interval subsequent to step (a) and prior to step (b) of 1 to 90 min, in particular of 15 to 30 min, preferably in the absence of light exposure.

### Claim 30 (depends on 21)

The method of claim 21, wherein the light used in step (b) has a wavelength spectrum of 360 nm to 440 nm.

### Claim 31 (depends on 21)

The method of claim 21, wherein the light of step (b) has a wavelength spectrum of 380 nm to 460 nm.

### Claim 32 (depends on 31)

The method of claim 31, wherein the light of step (b) has equal irradiance throughout the wavelength spectrum.

### Claim 33 (depends on 31)

The method of claim 31, wherein the light of step (b) has an irradiance peak at around 405 nm.

### Claim 34 (depends on 21)

The method of claim 21, wherein the exposure of step (b) has a duration of 30 min to 1 hour.

### Claim 35 (depends on 21)

The method of claim 21, wherein the exposure of step (c) has a duration of at least 5 minutes, preferably of 5-60 minutes.

### Claim 36 (depends on 21)

The method of claim 21, wherein the dermatological disease is a hyperproliferative disease, preferably keratosis, more preferably actinic keratosis; basal carcinoma, squamous cell carcinoma in situ, warts, acne, rosacea or an inflammatory or infectious dermatological condition.

### Claim 37

A method of treating or preventing a dermatological disease in a patient in need thereof comprising:
(a) topical application or subcutaneous injection of a composition comprising a photosensitizer to an area of the skin of said patient,
(b) exposure of at least said area of the skin to light with a wavelength spectrum of 360 nm to 460 nm for a duration of 30 min to 5 hours, preferably 1 to 3 hours, more preferably 1 to 2 hours, and
(c) exposure of at least said area of the skin to light with a wavelength spectrum of 570 nm to 670 nm.

### Claim 38 (depends on 37)

The method of claim 37, wherein the composition is formulated as a nanoemulsion comprising:
(a) at least one aqueous component, and
(b) a carrier, which comprises:
(i) at least one lipophilic component,
(ii) at least one surfactant and
(iii) at least one alcohol.

### Claim 39 (depends on 37)

A kit comprising a light source capable of emitting light with a wavelength spectrum and preferably also irradiance similar or identical to sun light and violet-blue light and an instruction manual for carrying out steps (b) and (c) of the method of claim 37.

### Claim 40 (depends on 37)

A light source capable of emitting light with a wavelength spectrum and preferably also irradiance similar or identical to sun light and violet-blue light and a controller, wherein the controller is programmed for carrying out steps (b) and (c) of the method of claim 37.
